Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients

The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales The post Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients appeared first on Pharmaceutical Business review.

Pfizer commits $100m to support development of new antibiotics

More than 20 biopharmaceutical companies have collaborated to establish the AMR Action Fund, which will help focus on medicines that address most resistant bacteria and life-threatening infections. The The post Pfizer commits $100m to support development of new antibiotics appeared first on Pharmaceutical Business review.

Moderna completes enrolment of phase 2 study of its mRNA vaccine against Covid-19

mRNA-1273 is Moderna’s second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the Company’s CMV Phase 2 study, which was fully The post Moderna completes enrolment of phase 2 study of its mRNA vaccine against Covid-19 appeared first on Pharmaceutical Business review.

Concert receives FDA breakthrough status for CTP-543 in alopecia areata

There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in The post Concert receives FDA breakthrough status for CTP-543 in alopecia areata appeared first on Pharmaceutical Business review.

AstraZeneca, Merck secure EU nod for Lynparza to treat germline BRCA-mutated metastatic pancreatic cancer

The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed The post AstraZeneca, Merck secure EU nod for Lynparza to treat germline BRCA-mutated metastatic pancreatic cancer appeared first on Pharmaceutical Business review.

Vor Biopharma closes $110m Series B financing

Proceeds will advance the company’s lead candidate VOR33 into clinical trials, deepen its portfolio, and accelerate the validation of additional targets for its scientific platform, which is designed The post Vor Biopharma closes $110m Series B financing appeared first on Pharmaceutical Business review.

Ridgeback begins enrolment for phase 2 Covid-19 trial of EIDD-2801

The trial of EIDD-2801 will be held using a newly launched Covid-19 drug testing platform called AGILE, which has been developed in the UK by the University of The post Ridgeback begins enrolment for phase 2 Covid-19 trial of EIDD-2801 appeared first on Pharmaceutical Business review.

FDA grants orphan drug designation to Neurogene’s gene therapy for treatment of CLN5 Batten disease

Batten disease, a common name for a rare class of diseases called neuronal ceroid lipofuscinoses (NCL), affects an estimated 2-4 out of every 100,000 children in the United The post FDA grants orphan drug designation to Neurogene’s gene therapy for treatment of CLN5 Batten disease appeared first on Pharmaceutical Business review.

Corvus begins phase 1 Covid-19 clinical trial with novel immunotherapy

The company is evaluating an agonistic (immunostimulatory) humanised monoclonal antibody, dubbed CPI-006, which is said to show a potential new approach to immunotherapy of infectious diseases and cancer. The post Corvus begins phase 1 Covid-19 clinical trial with novel immunotherapy appeared first on Pharmaceutical Business review.

VROBIO announces new patients dosed in Gaucher disease and cystinosis trials

The company also announced that the second patient has been dosed in the ongoing investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis. “The first patient dosed is an important The post VROBIO announces new patients dosed in Gaucher disease and cystinosis trials appeared first on Pharmaceutical Business review.